Socialiya - Entertainment. Knowledge. Community.
RAS Drug Nearly Doubles Survival in Mets Pancreatic Cancer

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, n...

HEALTH NEWS June 03, 2026

RAS Drug Nearly Doubles Survival in Mets Pancreatic Cancer

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common...

3 views 0 likes 0 comments
Share:
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common...

Author: Medscape

Read Original Article

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya